NeuroSense Therapeutics Ltd. Warrant (NRSNW)
Official siteBIOTECHNOLOGY • NASDAQ
Last updated: Nov 16, 2026 at 4:00 PM ET
NeuroSense Therapeutics Ltd. Warrant (NRSNW) Financials: Revenue, Profit and Cash Flow
NeuroSense Therapeutics Ltd. Warrant reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$11.13M, operating cash flow was -$7.67M and free cash flow was -$7.68M. The quarter ended Dec 31, 2025 had net income of -$3.21M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $11.09M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Dec 2025, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Cost of revenue | N/A | $22.00K | $97.00K | $89.00K | $3.00K | $3.00K | N/A |
| Gross profit | N/A | -$22.00K | -$97.00K | -$89.00K | -$3.00K | -$3.00K | N/A |
| Research and development | $6.23M | $5.70M | $7.27M | $6.42M | $3.08M | $2.50M | $898.00K |
| Operating income | -$11.09M | -$9.90M | -$12.05M | -$13.55M | -$5.59M | -$2.89M | -$1.24M |
| Net income | -$11.13M | -$10.21M | -$10.11M | -$12.34M | -$4.04M | -$2.83M | -$1.23M |
| EBITDA | N/A | -$9.88M | -$9.64M | -$12.23M | -$2.88M | -$2.83M | $13.00K |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$3.20M | -$3.20M | -$2.35M | -$2.35M | -$1.77M | -$2.11M | -$3.03M | -$2.99M | -$3.29M | -$2.90M | -$3.48M | -$2.99M |
| Net income | -$3.21M | -$3.21M | -$2.35M | -$2.35M | -$1.80M | -$2.15M | -$857.00K | -$5.40M | -$2.95M | $784.00K | -$5.22M | -$2.92M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $98.00K by $68.00K. Shareholder equity was negative, at -$1.56M, as total liabilities of $2.59M exceeded total assets of $1.03M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $1.03M | $4.58M | $3.19M | $7.71M | $11.43M | $779.00K | $955.00K |
| Current assets | $778.00K | $4.40M | $2.92M | $7.38M | $11.41M | $729.00K | $913.00K |
| Cash and equivalents | $166.00K | $3.38M | $2.64M | $3.54M | $11.06M | $699.00K | $895.00K |
| Total liabilities | $2.59M | $1.99M | $4.94M | $2.09M | $2.42M | $120.00K | $37.00K |
| Short-term debt | $98.00K | $73.00K | $69.00K | $64.00K | N/A | N/A | N/A |
| Shareholder equity | -$1.56M | $2.58M | -$1.76M | $5.62M | $9.01M | $659.00K | $918.00K |
Quarterly
| Line item | Jun 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $896.00K | $1.03M | $1.03M | $1.68M | $1.68M | $4.58M | $984.00K | $1.84M | $1.45M | $3.19M | $5.39M | $7.87M |
| Total liabilities | $3.00M | $2.59M | $2.59M | $2.20M | $2.20M | $1.99M | $3.80M | $3.54M | $8.44M | $4.94M | $5.58M | $9.41M |
| Cash and equivalents | $231.00K | $166.00K | $166.00K | $666.00K | $666.00K | $3.38M | $344.00K | $1.21M | $735.00K | $2.64M | $4.76M | $7.09M |
| Shareholder equity | -$2.10M | -$1.56M | -$1.56M | -$519.00K | -$519.00K | $2.58M | -$2.82M | -$1.70M | -$6.99M | -$1.76M | -$196.00K | -$1.54M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.67M | -$10.13M | -$8.35M | -$7.59M | -$1.54M | -$695.00K | -$582.00K |
| Capital expenditures | $8.00K | $3.00K | $29.00K | $70.00K | $17.00K | $9.00K | $7.00K |
| Free cash flow | -$7.68M | -$10.14M | -$8.38M | -$7.66M | -$1.56M | -$704.00K | -$589.00K |
| Investing cash flow | -$8.00K | $1.00K | $3.47M | -$3.54M | -$17.00K | -$9.00K | -$26.00K |
| Financing cash flow | $4.43M | $10.91M | $3.98M | $3.69M | $11.90M | $508.00K | $1.42M |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.84M | -$1.84M | -$2.00K | -$2.00K | N/A | N/A | N/A | N/A | N/A | N/A | $1.78K | N/A |
| Capital expenditures | $1.50K | $1.50K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | -$1.84M | -$1.84M | -$2.00K | -$2.00K | N/A | N/A | N/A | N/A | N/A | N/A | $1.78K | N/A |
Frequently Asked Questions About NRSNW
What is NeuroSense Therapeutics Ltd. Warrant's annual revenue?
NeuroSense Therapeutics Ltd. Warrant reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is NeuroSense Therapeutics Ltd. Warrant profitable?
No. NeuroSense Therapeutics Ltd. Warrant reported net income of -$11.13M for the fiscal year ended Dec 31, 2025.
How much free cash flow does NRSNW generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$7.67M minus capital expenditures of $8.00K produced free cash flow of -$7.68M.
How much debt does NeuroSense Therapeutics Ltd. Warrant have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $98.00K and cash and equivalents of $166.00K.
NRSNW pages: Overview, Financials